A subscriber to the Site had an interesting find of an article published in the Journal of Surgical Research, describing the placebo controlled clinical study of PAD (Peripheral Arterial Disease) patients with chronic ulcers treated with ADRCs from Celution. By my assessment this study is one of several European Celution device based clinical studies, which culminated in Cytori receiving market authorization (added claim to Celution for intended use of: therapy against chronic wounds- reported August 2012). As described in my other article: Another backdoor Slider, EU regulations allow the device pathway for same day surgical and AUTOLOGOUS procedures, whereby the extracted cells remain property of the patient and ONLY can be used for this SAME patient as per the "Placed on the Market" principle. This article is presented in "key elements" style instead of my usual long stories to keep our focus on the facts-